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The eosinophilia-myalgia syndrome (EMS) is a newly recognized illness that occurred in an epidemic form during the
summer of 1989. The illness was characterized in the acute phase by myalgia and eosinophilia, followed in many patients by
chronic cutaneous lesions, progressive neuropathy, and myopathy. EMS was associated with ingestion of L-trypto-phan, an
essential amino acid marketed as a nutritional supplement but widely used as a therapeutic agent. Evidence of abnormal
L-tryptophan metabolism has been described in patients with EMS, and most likely reflects increased activity of indoleamine
2,3-dioxygenase, the rate-limiting enzyme of tryptophan metabolism. A contaminant identified in EMS-associated
L-tryptophan preparations has been isolated and characterized, but its biologic effects and role as the etiologic agent in
EMS remain to be established. Pathologic observations and experimental studies indicate that eosinophils, mononuclear
inflammatory cells, and fibroblasts are potential effector cells, and interleukin-5 and transforming growth factor-b are
important mediators in the pathogenesis of the syndrome. Although few new cases of EMS occurred following the
withdrawal of L-tryptophan, affected patients continue to manifest late sequelae of the disease, including dermal fibrotic
conditions. This tragic outbreak of a newly recognized illness has focused interest on the role of chemical and
environmental agents in the pathogenesis of various idiopathic illnesses characterized by tissue inflammation and fibrosis.
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In October 1989, state health authorities in New Mexico identified a
cluster of patients with an unusual acute illness characterized by intense
myalgia and eosinophilia. Each patient had been ingesting L-tryptophan-
containing preparations (LTCP) for treatment of insomnia. As many
additional cases were identified from other states, the Centers for Disease
Control (CDC) proposed the term ‘‘eosinophilia-myalgia syndrome’’
(EMS) to designate the previously unknown syndrome, and established
the following criteria for the diagnosis: (1) peripheral blood eosinophil
count exceeding 1000/mm3, (2) generalized myalgia severe enough to
affect the patient’s ability to pursue usual daily activities, and (3) the
absence of other illnesses that could account for the eosinophilia [1]. A
case-control study initiated by the state health department in Oregon
showed that there was an unequivocal association between EMS and the
consumption of LTCP [2]. Following the recall of LTCP by the Food and
Drug Administration (FDA), the number of new cases of EMS reported to
the CDC decreased dramatically. As of June 1991, 1543 cases of EMS
had been registered, and it was suggested that the actual number may be
considerably higher [3]. Nearly one-third of the patients required
hospitalization, and 27 deaths directly attributable to EMS have been
reported [4].
CLINICAL FEATURES
Most EMS patients first developed symptoms between July 1989 and
February 1990. The dose of L-tryptophan ingested by these individuals
varied from 10mg to 15 g/d (median 1.5 g/d) [2]. The clinical presenta-
tion, laboratory findings, and pathologic features of EMS have been
described in a number of recent publications [5–13]. The frequency of
acute and chronic manifestations of the disease based on an analysis of
several studies [5–13] is summarized in Table I.
In its early phase (0–2 months), EMS was characterized by diffuse
myalgia, low-grade fever, swelling of the face and extremities, and a
variety of skin rashes. A substantial proportion of patients with EMS
developed a protracted course despite the discontinuation of LTCP use.
Approximately one-half of the patients developed cutaneous induration
resembling diffuse fasciitis or scleroderma [6,7,10,12]. These changes
frequently affected the extremities, but spared the hands and feet (Fig 1).
Histopathologic examination of full-thickness skin biopsy specimens
showed marked thickening of the fascia and dermis due to accumulation
of collagen and mucopolysaccharides, accompanied by inflammatory
cell infiltration with mononuclear cells and eosinophils (Fig 2). Diffuse
sensorimotor peripheral neuropathy and myopathy manifested by
paresthesias, painful muscle cramps, or proximal weakness were
frequent late sequelae [12,14,15]. Other chronic manifestations of EMS
include pulmonary hypertension, cardiac arrhythmias and cardiomyo-
pathy, hypothyroidism, alopecia, and cognitive abnormalities [6,10–13].
Most patients had striking peripheral blood eosinophilia in the initial
phase of the illness. Bone marrow examination showed eosinophilic
hyperplasia with normal precursor maturation. In contrast to other
disorders associated with eosinophilia, IgE levels were not elevated in the
serum of EMS patients [10].
Treatment with glucocorticoids resulted in improvement of the acute
manifestations of EMS, and in rapid decrease of the peripheral blood
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eosinophil count. However, skin induration, myopathy, or neuropathy
generally responded poorly to glucocorticoids, and the long-term
outcome of patients treated with glucocorticoids was not statistically
different from that of untreated patients [13–16]. Other treatments have
been reported to be of benefit in EMS, but in the absence of controlled
trials, these results are difficult to interpret. At the time of this writing,
some 2 years after the EMS epidemic, the full clinical spectrum, natural
history, optimal therapy, and long-term prognosis of this novel disease
are unknown.
ETIOLOGY
Immediately following the recognition of the EMS epidemic and the
realization of its magnitude, intense research efforts were undertaken to
identify the cause of the disease. Although the specific etiologic
mechanisms have not been fully elucidated to date, two hypotheses
have been advanced: (1) EMS is triggered by a contaminant in LTCP that
arises as a by-product of the manufacturing process or is introduced
exogenously; and (2) EMS develops in predisposed individuals who have
an inborn or acquired alteration in the enzymes involved in L-tryptophan
metabolism. In the following section, we will critically review the data
supporting these alternatives.
Although EMS appears to be a ‘‘new’’ disease, clinical and pathologic
similarities between EMS and several previously described idiopathic
syndromes associated with eosinophilia were recognized. Prominent
among these are eosinophilic fasciitis (EF), idiopathic hypereosinophilic
syndrome (IHES), and toxic oil syndrome (TOS). Each of these conditions
Figure 1. Induration of the skin in EMS. Note that the hands are unaffected (A), whereas the forearm is hidebound (B).
Table I. Prominent Clinical Manifestations of EMSa
Clinical Manifestation Frequency (%)
Early (0–2 months)
Myalgia 100
Skin rash 71
Edema 52
Fever 41
Arthralgia 35
Respiratory symptoms 32
Late (2 months to 1 year)
Weight loss 50
Muscle weakness 44
Paresthesia 42
Scleroderma-like induration 42
Xerostomia 36
Alopecia 33
aData compiled from [10–13].
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is characterized by eosinophilia, infiltration of various tissues by mature
eosinophils, and some degree of visceral organ dysfunction. EF, a
relatively uncommon idiopathic condition first described by Shulman in
1974, is characterized by diffuse fasciitis and peripheral blood
eosinophilia. Although significant internal organ involvement is un-
common, the fascial inflammatory process may extend deep into the
muscle [16]. It has been pointed out that many patients diagnosed as
having EF before 1989 were retrospectively found to have ingested LTCP
prior to becoming ill [17]. Some of these may have been pre-epidemic
cases of L-tryptophan-associated EMS [18]. In fact, it has been suggested
that EF and EMS are identical diseases. However, despite similarities
between the two syndromes, a careful analysis shows that several clinical
and laboratory features clearly distinguish EF from EMS, indicating that
they are related but distinct clinical entities [19].
EMS bears a particularly striking resemblance to TOS. TOS was an
explosive illness associated with eosinophilia and multisystem manifes-
tations in the acute stages, and the development of late sequelae
including chronic skin induration in many patients. The TOS epidemic,
which swept Spain in 1981, affected over 20 000 people and was
associated with significant mortality and morbidity [20]. The outbreak of
the TOS epidemic was attributed to consumption of denatured rapeseed
oil originally intended for industrial use. Similarities between EMS and
TOS include the abrupt onset of symptoms and eosinophilia, the
development of chronic neuromuscular manifestations in a subset of
patients despite discontinuation of the etiologic agent (contaminant), a
female predominance in the late stages of the disease, abnormalities in
tryptophan metabolism, and evidence of striking eosinophil infiltration
and degranulation in affected tissues [21]. Despite intensive investigation
during the past decade, the responsible etiologic agent of TOS has not
been identified to date and no animal models of this disease have been
generated [22].
L-Tryptophan The virtually universal association between L-tryptophan
ingestion and the development of EMS in the 1989 epidemic suggests the
existence of a cause-effect relationship. L-tryptophan is an indole amino
acid that must be obtained from dietary sources. Although it is the least
abundant amino acid in most proteins, tryptophan is converted into a
large number of biologically important metabolites [23]. The activity of
the enzymes regulating tryptophan metabolism is influenced by several
factors, including corticosteroids, alcohol, and anti-depressant medica-
tions, as well as by interferon [23]. Whereas most dietary L-tryptophan
is utilized in protein synthesis, a small fraction is metabolized via
two pathways (Fig 3). In peripheral tissues, greater than 90% of the
L-tryptophan not required in protein synthesis undergoes oxidation to
formylkynurenine. This step is catabolized by the enzymes tryptophan
2,3-dioxygenase in the liver and indoleamine 2,3-dioxy-genase (IDO) in
extrahepatic tissues. Following a series of intermediate steps, quinolinic
Figure 2. Histopathologic findings in EMS. (A) Abundant eosinophils in the
deep dermis are in proximity to undulating collagen fibers. (B) Many
eosinophils are juxtaposed to fibroblasts (hematoxylin and eosin,
magnification 100) (from [6]).
Figure 3. Metabolic pathways of L-tryptophan in humans. Important enzymes
are indicated in italics. Vitamin B6 (pyridoxine) is required for some
metabolic steps, as shown.
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acid, a potent endogenous neurotoxin, is generated from kynurenine in
this pathway. Quinolinic acid has been the subject of great interest,
because it has been implicated in the pathogenesis of several metabolic
and neurologic conditions. Recent evidence suggests that quinolinic
acid also plays a role in the encephalopathy associated with human
immunodeficiency virus infection [24]. A rise in plasma L-tryptophan
induces the activity of IDO, and therefore augments the biosynthesis of
kynurenines. Importantly, extracellular fluid levels of quinolinic acid
following L-tryptophan loading may equal or even exceed those that
have been shown to be neurotoxic in vitro [25].
The minor metabolic pathway of L-tryptophan involves its hy-
droxylation to 5-hydroxytryptophan, and occurs primarily in the central
nervous system. 5-hydroxytryptophan may undergo decar-boxylation
to 5-hydroxytryptamine (serotonin), an important neurotransmitter and
a potent vasoconstrictor. Although the serotonin pathway normally
accounts for only 1–3% of L-tryptophan metabolism, large amounts of
dietary L-tryptophan may be diverted to this metabolic pathway in
patients with functioning carcinoid tumors.
Ingestion of 0.5–1.0 g of L-tryptophan causes behavioral alterations in
humans, including drowsiness [26]. Because serotonin plays an
important role in the mediation of sleep, it has been assumed that the
somniferous effects of L-tryptophan result from increased availability of
serotonin in the brain [27]. Despite inconclusive evidence for its
effectiveness, L-tryptophan has been widely promoted for the treatment
of a variety of problems including insomnia, pre-menstrual tension,
obesity, and depression. In the United States, LTCP were not labeled for
these medical indications but were sold as food supplements, and as such
were not subject to regulatory control by the FDA. By 1989, more than
2% of households had at least one member who was consuming LTCP
[28]. Prior to the outbreak of the EMS epidemic, some investigators
suggested that excessive L-tryptophan ingestion may result in accumula-
tion of toxic levels of quinolinic acid in the central nervous system [29]. It
has also been pointed out that amino acids ingested as supplements were
metabolized quite differently than amino acids ingested from dietary
sources, and should be considered to be drugs rather than food
supplements [30]. However, with the exception of a transient ‘‘serotonin
reaction’’ characterized by paresthesia and myoclonus, seen in some
individuals taking L-tryptophan in combination with anti-depressant
medications containing monoamine oxidase inhibitors [31], few adverse
effects of L-tryptophan have been reported.
The epidemic nature of EMS, and its apparent rarity in countries
where the processing and distribution of LTCP is carefully regulated (such
as Canada), suggest that a contaminant or by-product in the L-tryptophan
preparations, rather than abnormalities of its metabolism, may have been
responsible for the development of EMS. Furthermore, there is no
evidence that L-tryptophan or related compounds participate in the
activation or degranulation of eosinophils. It is of great interest, therefore,
that a large body of clinical and experimental observations accumulated
during the past three decades suggests that L-tryptophan – derived
compounds or alterations in L-tryptophan metabolic pathways may have
a role in the pathogenesis of certain features of EMS. Particularly
intriguing in this regard is the evidence linking L-tryptophan and related
compounds to abnormal fibrogenesis (Table II). For example, it has been
shown that serotonin stimulates collagen synthesis in vitro, and causes
fibrosis in experimental animals [32,33]. Patients with carcinoid
syndrome occasionally develop cutaneous and retroperitoneal fibrosis
[34]. The distribution of skin induration in these cases closely resembles
that observed in EMS, i.e., proximal fibrosis with sparing of the hands
and feet.
Systemic sclerosis and scleroderma-like syndromes are associated
with alterations in both pathways of normal tryptophan metabolism. For
example, increased serum levels of tryptophan metabolites have been
demonstrated in East African populations that subsist on a diet rich in
bananas and have a high frequency of endocardial fibrosis [35]. In
patients with systemic sclerosis, an exaggerated rise in serum levels of
kynurenine and urinary excretion of quinolinic acid following tryptophan
loading has been described [36]. Several studies that evaluated
tryptophan metabolism in patients with EMS found that their plasma
concentrations of kynurenine were higher than in healthy individuals
[7,14,37]. Untreated EMS patients with the most active disease displayed
the most significant elevations in kynurenine [7,14]. We examined
cerebrospinal fluid levels of quinolinic acid in EMS patients and
demonstrated a marked increase associated with neuropathy [14].
Although these observations implicate quinolinic acid in the develop-
ment of EMS neuropathy, quinolinic acid causes an axon-sparing
neurologic lesion, unlike that seen in EMS [38]. Whereas the specific
biochemical abnormalities responsible for these alterations in tryptophan
metabolism have not been identified, it is currently thought that
increased activity of the rate-limiting enzyme IDO is responsible for
the increase in kynurenine pathway intermediates in EMS [7]. IDO is
readily induced by a variety of cytokines in vitro, and is activated in
patients treated with such cytokines [39]. Although it has been proposed
that EMS-associated LTCP directly trigger activation of IDO, recent
studies examining the effect of L-tryptophan preparations on normal
mononuclear cells in vitro indicated that EMS-associated LTCP did not
induce increased IDO activity in these cells [40]. Alterations in
tryptophan metabolism in EMS are unlikely to be primary phenomena
and probably reflect activation of IDO by inflammatory mediators.
Nevertheless, elevated levels of certain tryptophan metabolites may exert
direct toxicity on tissues or may promote abnormal fibrogenesis. Those
possibilities need to be carefully examined.
TOXICOLOGY OF L-TRYPTOPHAN
Persuasive arguments have been advanced to support the possibility that
contaminated L-tryptophan preparations were responsible for the out-
break of EMS. At the time of the epidemic, bulk L-tryptophan was
produced by several manufacturers, each located in Japan. Following
importation to the United States, L-tryptophan was packaged in the form
of capsules and tablets and sold as nutritional supplements [41]. Almost
200 brands of LTCP were in use in the United States in 1989, but the
development of EMS was associated only with batches of L-tryptophan
originating from a single manufacturer (Showa-Denko, Tokyo) [41]. This
distribution pattern indicated a point-source contaminant. The possible
etiologic role of a contaminant is suggested by the observation that EMS-
associated LTCP cause secretion of cytokines, including granulocyte/
Table II. Association of Tryptophan and Related
Biogenic Amines with Tissue Fibrosis
In vivo fibrosis
Methysergide
Bananas, plantains
Carcinoid syndrome
Eosinophilia-myalgia syndrome
Animal and in vitro models
Subcutaneous fibrosis
Synovial fibrosis
Stimulation of collagen synthesis
Idiopathic fibrosing syndromes
Eosinophilic fasciitis (Shulman’s syndrome)
Systemic sclerosis
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mono-cyte colony-stimulating factor (GM-CSF) from normal peripheral
blood mononuclear cells in vitro [42]. No such effect was noted with
non-EMS-associated tryptophan lots. Furthermore, Crofford and collea-
gues recently were able to induce a syndrome with features of EMS using
implicated L-tryptophan [43]. These investigators found that administra-
tion of EMS-associated L-tryptophan to rats caused inflammation of the
subcutaneous fascia and perimysium. The changes could only be
induced in Lewis rats, a strain highly susceptible to a variety of
inflammatory illnesses. The affected animals did not develop blood
eosinophilia or histologic evidence of pulmonary or skin involvement.
DeSchryver-Kecskemeti and colleagues found increased perivascular
inflammatory infiltrates and mast cell de-granulation in small intestinal
lamina propria of rats treated with EMS-associated L-tryptophan [44].
Animals treated with vehicle control or pure L-tryptophan did not show
similar histopathologic abnormalities.
Mass production of L-tryptophan involves a bacterial fermentation
process during which multiple secondary metabolites may be generated.
Several purification steps, including adsorption with activated carbon
and reverse-osmosis membrane filtration must be employed to remove
cellular debris, by-products, and other impurities [28]. Analysis of the
manufacturing conditions at Showa-Denko revealed that between
December 1988 and June 1989 several changes in L-tryptophan
production were instituted. These included the use of a new bacterial
strain (strain V) of Bacillus amyloli-quefaciens that had been genetically
manipulated to produce L-tryptophan with a high yield, bypass of the
reverse-osmosis filtration step, and reduction in the amount of powdered
activated carbon used for purification. A significant correlation between
the reduction of powdered activated carbon and the development of EMS
was noted.
Analysis of EMS-associated L-tryptophan lots by high-performance
liquid chromatography (HPLC) indicated the presence of numerous peaks
beside tryptophan, each corresponding to one or more chemical
impurities [28]. A single absorbance peak with a retention time of
25min was consistently found in EMS-associated L-tryptophan lots. This
peak, labeled ‘‘peak E’’ by investigators at the Mayo Clinic, is identical to
peak 97 demonstrated by the CDC [45]. The contaminant represented by
‘‘peak E’’ has been isolated and purified. Analysis by a variety of
techniques indicated the structure 1,10-eth-ylidenebisftryptophan] (EBT)
[46,47]. EBT appears to be a novel amino acid, composed of a
tryptophan dimer with two L-tryptophan molecules joined together by
an ethylidene bridge between the two indole ring nitrogens (Fig 4). As
implicated lots of LTCP contained 99.5% pure L-tryptophan, the
contaminant represented by ‘‘peak E’’ or its breakdown products was
present in very small amounts, and must have had extremely high
biologic activity in order to trigger EMS. Alternately, ‘‘peak E’’ may be a
surrogate marker for other etiologic substance(s). Indeed, numerous
additional peaks have been demonstrated by HPLC analysis of Showa-
Denko-produced L-tryptophan. These include 1-methyl-1,2,3,4-tetrahy-
dro-b carboline, which may be generated by hydrolysis of EBT, and
various tryptophan breakdown products, as well as a baci-tracin-like
contaminant [48].
The consumption of Showa-Denko’s LTCP was not uniformly
associated with the development of EMS. In one cohort study,
approximately half of the patients ingesting more than 4g/d of
L-tryptophan originating from Showa-Denko became ill, whereas the
attack rate was substantially lower in those ingesting less than this amount,
suggesting a critical threshold dose of exposure necessary to trigger EMS
[49]. In addition to exposure to the etiologic agent, individual predisposi-
tion may also play a role in determining the risk of developing EMS.
PATHOGENESIS
The Role of the Eosinophil The striking eosinophilia in the blood and in
some tissues of patients with EMS implicates eosinophils as effector cells
in the syndrome. The growth and maturation of eosinophils in the bone
marrow, their migration to sites of inflammation, and their viability and
function are regulated by three cytokines. Interleukin-3 (IL-3), IL-5, and
GM-CSF are produced by activated T lymphocytes, mast cells,
neutrophils, and eosinophils themselves [50,51]. These cytokines
promote the development of eosinophil precursors, enhance the
eosinophil’s ability to respond to chemotactic factors, and stimulate the
conversion of normal eosinophils to eosinophils with abnormally low
sedimentation density (hypodense eosinophils) in vivo and in vitro [52].
Hypodense eosinophils are activated cells with increased expression of
complement receptors, prolonged survival in vitro, and markedly
enhanced release of leukotrienes and other inflammatory mediators
[53]. The proportion of hypodense eosinophils in the blood is increased
in hypereosinophilic disorders, indicating activation mediated by eo-
sinophilopoitins. IL-5, in particular, has been implicated in the abnormal
eosinophil proliferation and activation characteristic of IHES [54].
Cytokine-induced stimulation of eosinophils appears to be an
important feature of EMS. Gradient sedimentation analysis of eosinophils
isolated from patients with EMS revealed a fourfold increase in the
proportion of hypodense cells, compared to eosinophils from normal
donors [55]. Furthermore, EMS sera, but not normal human sera,
markedly increased the ex vivo viability of normal eosinophils. This
effect was attenuated by a neutralizing antibody to IL-5. These
observations indicate that EMS sera have increased IL-5 activity and
suggest that IL-5 may be responsible for the eosinophilia and elevated
proportion of hypodense eosinophils primed for augmented biologic
response to activating stimuli.
Activated eosinophils release toxic granule proteins, including major
basic protein (MBP) and eosinophil-derived neurotoxin (EDN) at sites of
inflammation. Determination of urine and serum levels of MBP and EDN
showed marked elevation in patients with EMS, indicating ongoing
eosinophil degranulation [5,8]. In addition, striking extracellular deposi-
tion of MBP was demonstrated by immunofluorescence in the lung,
myocardium, muscle, and other affected tissues, suggesting that
eosinophil-derived granule proteins may contribute to tissue injury in
EMS [8]. Although eosinophil activation is clearly important in the
pathogenesis of EMS, severe injury has been noted in tissues in the
Figure 4. Structure of L-tryptophan and of the compound represented by
‘‘peak E.’’ This compound is l,l0-ethylidenebis[tryptophan] (EBT), a dimer
formed by two L-tryptophan molecules joined by an ethylidene bridge
between the two indole ring nitrogens.
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absence of eosinophils or their degranulation products. These observa-
tions imply that infiltration and degranulation by eosinophils cannot be
entirely responsible for the full spectrum of pathology in EMS [8].
Autoimmune Mechanisms Recent observations indicate that in EMS,
both cellular and humoral autoimmune mechanisms may contribute to
tissue injury (Table III). The cellular immune abnormalities in EMS
include the presence of activated lymphocytes and mononuclear cells in
muscle and fascia, alterations in peripheral blood mononuclear cell
phenotypes, and increased expression of surface activation markers on
circulating T lymphocytes. Examination of muscle biopsy specimens in
EMS reveals an often striking inflammatory infiltrate, composed
predominantly of mononuclear cells. In contrast to idiopathic inflam-
matory myositis, EMS is characterized by perimyositis, with infiltrating
cells found almost exclusively at perivascular, perimysial, and fascial
locations [8,14]. Quantitative immunocytochemical analysis demon-
strated a predominance of activated T cells at these sites [56].
Macrophages account for 20–40% of infiltrating cells. Eosinophils are
only rarely noted in muscle biopsy specimens, despite peripheral blood
eosino-philia at the time of the biopsy. Analysis of peripheral blood
mononuclear cells indicated alterations in CD4þ cell subpopulations
reflecting activation of T cells, as well as a reduction in suppressor-
inducer T cells with a concomitant increase in the helper-inducer
population [53].
Abnormal humoral immunity is evidenced by the frequent occur-
rence of antinuclear antibodies (ANA) in EMS, but the extent to which
autoantibodies contribute to the pathogenesis is unclear. By indirect
immunofluorescence on Hep-2 cell substrate, circulating ANAs can be
detected in up to 50% of patients [8,10,12]. Specific antibodies
associated with autoimmune diseases, such as antibodies to the
extractable nuclear antigens Sm and RNP, Ro, La, topoiso-merase-1,
and kinetochore, have not been described in EMS. We recently evaluated
autoantibodies in a large group of EMS patients by immunoprecipitation.
Several polypeptides were recognized by EMS sera, including a 105-kD
polypeptide that was immunoprecipi-tated by sera from 15% of the
patients (Targoff I, Varga J, KaufFman L, Jimenez SA: unpublished
observations). The antigens recognized by autoantibodies in EMS sera
have not been characterized to date. In one EMS patient with chronic
neuromuscular involvement, high titers of an autoantibody reacting with
the nuclear membrane were detected by indirect immunofluorescence,
and were identified as anti-lamin C by immunoblotting to purified lamin
C. Autoantibodies with this specificity have been described previously
only in patients with chronic hepatitis delta infection [57]. Anti-lamin C
antibody titer decreased in this case following discontinuation of
L-tryptophan ingestion and treatment with glucocorticoids [59].
Fibrosis Fibrosis of the dermis and fascia, perimysium and peri-neurium,
and connective tissue surrounding blood vessels is the most dramatic
histopathologic finding in late EMS. Massive accumulation of collagen,
fibronectin, and other extracellular matrix components occurs at these
sites (Fig 5). Increased expression of the corresponding genes has been
demonstrated [6,58]. Fibroblasts derived from the involved skin of
patients with untreated EMS show increased rates of collagen synthesis
and transcription of the al(l)procollagen gene in vitro compared to age
and sex-matched healthy controls [60]. These alterations appear to
Table III. Immunologic Abnormalities in EMS
Cellular
Inflammatory cell infiltration in fascia, muscle:
Monocytes, macrophages, lymphocytes
Activated mononuclear cells
In tissue
In blood
Preponderance of CD8+ T cells in affected tissues
Humoral
Circulating immune complexes
Antinuclear autoantibodies
Figure 5. Excessive deposition of fibronectin (A) and type VI collagen (B) in the subcutaneous fascia, as demonstrated by indirect immunofluorescence of a
biopsy specimen from affected skin in EMS. (From [58].)
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persist during several serial passages. Numerous fibroblasts displaying
elevated procollagen mRN A levels were found in the dermis and fascia
by in situ hybridization of biopsy specimens from involved skin in
patients with EMS [6]. These studies also demonstrated an absence of
topographic association between eosinophils and biosynthetically active
fibroblasts, suggesting that direct cell-cell interactions may not be
required for the activation of fibroblast connective tissue production in
EMS [58]. In addition to increased synthesis of extracellular matrix
components, EMS fibroblasts in situ also display elevated expression of
the gene for transforming growth factor b1, (TGF-b1) (Fig 6) [58], TGF-b1,
plays a critical role in the physiologic regulation of connective tissue
metabolism, and appears to participate in the pathogenesis of several
experimentally induced and spontaneously occurring fibrotic conditions
[56–58,60–62]. Although direct confirmation is lacking, the evidence
from immunohistologic and in situ hybridization studies suggests that
TGF-b1 may mediate the development of EMS-associated fibrosis via
autocrine and paracrine mechanisms.
Additional cytokines and cells may also contribute to fibrogenesis in
EMS. Of particular interest in this regard is the potential role of
eosinophils. The participation of eosinophils in the development of
fibrosis is supported by several recent observations. Crude eosinophil
extracts have been shown to induce fibroblast proliferation and
glucosamine synthesis in vitro [63], and eosinophil-derived granule
proteins induce secretion of platelet a granule components, including
fibrogenic cytokines such as TGF-b [64]. Furthermore, under certain
circumstances eosinphils synthesize and secrete transforming growth
factor a, which is a potent stimulus for fibroblast proliferation [65].
Therefore eosinophils are capable of elaborating potentially fibrogenic
cytokines and other, as yet unidentified, mediators that may contribute to
connective tissue activation. An important role for eosinophils in the
pathogenesis of pathologic fibrosis is also indicated by the recent
demonstration of eosinophil activation in systemic sclerosis, a prototypic
human fibrotic disease [66]. In this study, serum levels of eosinophil
degranulation products were found to be markedly increased in patients
with systemic sclerosis. In addition, degranulation was demonstrated by
immuno-cytochemistry in the affected skin of these patients.
A hypothetical scheme combining these pathogenetic mechanisms is
shown in Fig 7. The initial triggering agent of EMS, such as a contaminant
Figure 6. Expression of TGF-b in EMS. A,B: peroxidase – anti-peroxidase staining
for TGF-b protein. Note positive immunoreaction in association with cells of lower
epidermis (A) and within a subpopulation of fibroblastic cells in the fascia (B,
arrow), whereas the majority of the cells are negative (B, open arrows). C: in situ
hybridization with a cDNA for TGF-b1. The autoradiographic grains represent
radiolabeled cDNA/mRNA hybrids. The TGF-b1, gene is expressed in the fascia by
a subpopulation of fibroblastic cells (arrows). Most of the cells, however, are
negative (open arrows), in a pattern resembling that noted for TGF-b1, protein
(hematoxylin counterstain). Bar, 50mm (from [58]).
Figure 7. Overview of the pathogenesis of EMS, emphasizing the role of
effector cells and regulatory cytokines (see text for discussion). MBP, major
basic protein; PDGF, platelet-derived growth factor; ECP, eosinophil cat-ionic
protein; EDN, eosinophil-derived neurotoxin; ECM, extracellular matrix.
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in LTCP, activates inflammatory cells including lymphocytes, monocytes,
and perhaps other cells. These cells are induced to secrete cytokines that
cause activation of eosinophils (IL-5, GM-CSF) and fibroblasts (TGF-b).
Activated eosinophils may release cytokines, toxic granule contents, and
other inflammatory substances, resulting in amplification of the immune
response and tissue injury. Activated fibroblasts produce increased
amounts of collagen and other extracellular matrix components. These
cells may also undergo autoinduction via TGF-b, thus perpetuating the
fibrotic response.
CONCLUSIONS
Although the clinical and pathologic features of EMS are well
characterized, the etiology and pathogenesis of this recently described
disease remain poorly understood. The presence of trace impurities in
some LTCP was associated with the development of EMS, and
preliminary results from in vitro studies and from a rodent model of the
disease support the possibility of a contaminant as the etiologic factor. A
compound highly associated with EMS has been identified and
characterized, but its role as an etiologic agent in the syndrome has
not been established. At the same time, abnormalities in the metabolism
of tryptophan have been demonstrated in some EMS patients. These
abnormalities could play a role in the pathogenesis of EMS or may simply
reflect inflammation. It may be that the development of EMS is triggered
by an interaction of these two factors, i.e., the introduction of a
contaminant of LTCP and abnormal metabolism of L-tryptophan in
predisposed hosts. Activation and degranulation of eosinophils, possibly
mediated by cytokines, appear to be important early events. In addition,
cellular immune mechanisms appear to be responsible for many of the
clinical and pathologic manifestations of EMS. Toxic tryptophan
metabolites, such as the neurotoxin quinolinic acid are generated in
excess, and may also contribute to tissue injury. The recognition that
consumption of a widely used essential amino acid sold as a food
supplement, and not subject to regulatory control, may result in the
development of a serious multisystem disease with chronic autoimmune
features has focused interest in the potential role of chemical and
environmental agents in triggering idiopathic eosinophilic and fibrotic
disorders. Careful study of the EMS epidemic will undoubtedly enhance
our understanding of these incurable illnesses, and will be of great value
in efforts to develop new strategies for their prevention and treatment.
Furthermore, the tragic epidemic also emphasizes that amino acids and
other ‘‘nutritional supplements’’ must be regulated when they are used as
drugs.
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